Literature DB >> 17485437

Stable serum levels of anti-Müllerian hormone during the menstrual cycle: a prospective study in normo-ovulatory women.

S Tsepelidis1, F Devreker, I Demeestere, A Flahaut, Ch Gervy, Y Englert.   

Abstract

BACKGROUND: Anti-Müllerian hormone (AMH), secreted by the granulosa cells of preantral and small antral follicles, has been described as a potential marker of the ovarian reserve. The aim of this prospective study is to investigate the variations of AMH during the menstrual cycle in a young selected population of normo-ovulatory women and to analyse the correlation with other cyclic hormones.
METHODS: Twenty healthy volunteers from 19 to 35 years old, with regular menstrual cycles (26-31 days), normal ovulation (day 10-16), normal hormonal profile and normal body mass index (18-26 kg/m2) were recruited. AMH, inhibin B, LH, FSH, estradiol and progesterone were measured on days 3, 7, 10, 11, 12, 13, 14, 15, 16, 18, 21 and 25 of a spontaneous cycle.
RESULTS: AMH serum levels, either expressed by cycle day or aligned according to the ovulation day, did not show any significant variations during the menstrual cycle.
CONCLUSIONS: No significant fluctuation of the AMH level during the menstrual cycle was observed. Therefore, this hormone is particularly interesting for clinical evaluation of the ovarian reserve as it may be used at any time during the cycle.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17485437     DOI: 10.1093/humrep/dem101

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  59 in total

1.  Circulating anti-Müllerian hormone and breast cancer risk: A study in ten prospective cohorts.

Authors:  Wenzhen Ge; Tess V Clendenen; Yelena Afanasyeva; Karen L Koenig; Claudia Agnoli; Louise A Brinton; Joanne F Dorgan; A Heather Eliassen; Roni T Falk; Göran Hallmans; Susan E Hankinson; Judith Hoffman-Bolton; Timothy J Key; Vittorio Krogh; Hazel B Nichols; Dale P Sandler; Minouk J Schoemaker; Patrick M Sluss; Malin Sund; Anthony J Swerdlow; Kala Visvanathan; Mengling Liu; Anne Zeleniuch-Jacquotte
Journal:  Int J Cancer       Date:  2018-02-08       Impact factor: 7.396

Review 2.  Ovarian reserve evaluation: state of the art.

Authors:  Bruno Ramalho de Carvalho; Ana Carolina Japur de Sá Rosa e Silva; Júlio César Rosa e Silva; Rosana Maria dos Reis; Rui Alberto Ferriani; Marcos Felipe Silva de Sá
Journal:  J Assist Reprod Genet       Date:  2008-08-05       Impact factor: 3.412

3.  Prediction of high ovarian response to controlled ovarian hyperstimulation: anti-Müllerian hormone versus small antral follicle count (2-6 mm).

Authors:  Abbas Aflatoonian; Homa Oskouian; Shahnaz Ahmadi; Leila Oskouian
Journal:  J Assist Reprod Genet       Date:  2009-06-20       Impact factor: 3.412

4.  Antral follicle count determines poor ovarian response better than anti-Müllerian hormone but age is the only predictor for live birth in in vitro fertilization cycles.

Authors:  Mehmet Firat Mutlu; Mehmet Erdem; Ahmet Erdem; Sule Yildiz; Ilknur Mutlu; Ozgur Arisoy; Mesut Oktem
Journal:  J Assist Reprod Genet       Date:  2013-03-19       Impact factor: 3.412

Review 5.  Chemotherapy-induced damage to ovary: mechanisms and clinical impact.

Authors:  Giuliano Bedoschi; Paula Andrea Navarro; Kutluk Oktay
Journal:  Future Oncol       Date:  2016-07-12       Impact factor: 3.404

6.  Impact of breast cancer on anti-mullerian hormone levels in young women.

Authors:  H I Su; S W Flatt; L Natarajan; A DeMichele; A Z Steiner
Journal:  Breast Cancer Res Treat       Date:  2012-12-09       Impact factor: 4.872

7.  Anti-Müllerian hormone and inhibin B variability during normal menstrual cycles.

Authors:  MaryFran Sowers; Daniel McConnell; Katherine Gast; Huiyong Zheng; Bin Nan; Jenifer D McCarthy; John F Randolph
Journal:  Fertil Steril       Date:  2009-12-06       Impact factor: 7.329

8.  Serum antimüllerian hormone predicts ovarian reserve in a monkey model.

Authors:  Susan E Appt; Thomas B Clarkson; Haiying Chen; Michael R Adams; Patricia J Christian; Patricia B Hoyer; Mark E Wilson; Jay R Kaplan
Journal:  Menopause       Date:  2009 May-Jun       Impact factor: 2.953

9.  Luteal phase dynamics of follicle-stimulating and luteinizing hormones in obese and normal weight women.

Authors:  Lauren W Roth; Amanda A Allshouse; Erica L Bradshaw-Pierce; Jennifer Lesh; Justin Chosich; Wendy Kohrt; Andrew P Bradford; Alex J Polotsky; Nanette Santoro
Journal:  Clin Endocrinol (Oxf)       Date:  2014-03-20       Impact factor: 3.478

Review 10.  Recommendations for Premature Ovarian Insufficiency Surveillance for Female Survivors of Childhood, Adolescent, and Young Adult Cancer: A Report From the International Late Effects of Childhood Cancer Guideline Harmonization Group in Collaboration With the PanCareSurFup Consortium.

Authors:  Wendy van Dorp; Renée L Mulder; Leontien C M Kremer; Melissa M Hudson; Marry M van den Heuvel-Eibrink; Marleen H van den Berg; Jennifer M Levine; Eline van Dulmen-den Broeder; Natascia di Iorgi; Assunta Albanese; Saro H Armenian; Smita Bhatia; Louis S Constine; Andreas Corrias; Rebecca Deans; Uta Dirksen; Clarisa R Gracia; Lars Hjorth; Leah Kroon; Cornelis B Lambalk; Wendy Landier; Gill Levitt; Alison Leiper; Lillian Meacham; Alesandro Mussa; Sebastian J Neggers; Kevin C Oeffinger; Alberto Revelli; Hanneke M van Santen; Roderick Skinner; Andrew Toogood; William H Wallace; Riccardo Haupt
Journal:  J Clin Oncol       Date:  2016-07-25       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.